A detailed history of Orbimed Advisors LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 6,086,001 shares of LYEL stock, worth $6.69 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
6,086,001
Previous 6,405,098 4.98%
Holding current value
$6.69 Million
Previous $9.29 Million 9.57%
% of portfolio
0.2%
Previous 0.22%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.13 - $1.88 $360,579 - $599,902
-319,097 Reduced 4.98%
6,086,001 $8.4 Million
Q2 2024

Aug 14, 2024

BUY
$1.3 - $3.01 $8.07 Million - $18.7 Million
6,205,598 Added 3110.58%
6,405,098 $9.29 Million
Q1 2024

May 15, 2024

BUY
$1.71 - $3.07 $341,145 - $612,465
199,500 New
199,500 $444,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $273M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.